Galectin-1, the prototype of a family of β-galactosidebinding proteins, has been implicated in a wide variety of biological processes. Data presented herein show that galectin-1 stimulates monocyte migration in a dosedependent manner but is not chemotactic for macrophages. Galectin-1-induced monocyte chemotaxis is blocked by lactose and inhibited by an anti-galectin-1 antibody but not by nonspecific antibodies. Furthermore, galectin-1-mediated monocyte migration was significantly inhibited by MEK inhibitors in a rapid, time-dependent manner suggesting that MAP kinase pathways are involved in galectin-1. Migration was also almost completely blocked by pertussis toxin implying G-protein involvement in the galectin-1-induced chemotaxis. These results demonstrate a role for galectin-1 in monocyte chemotaxis which differs from galectin-3 in that macrophages are nonresponsive. Furthermore, our observations suggest that galectin-1 may be involved in chemoattraction at sites of inflammation in vivo and may contribute to disease processes such as atherosclerosis.
Introduction
Galectin-1 is a 14.5 KDa β-galactoside-binding protein belonging to the galectin family. This family comprises 15 members that are evolutionarily highly conserved, expressed by many different cell types including immune cells, and are involved in numerous cellular processes (Rubinstein et al. 2004 ). Extracellular functions reported for galectins include chemotaxis, apoptosis, cell growth regulation, and cell adhesion. Furthermore, a growing body of evidence suggests that galectins in general may play a pivotal role in the initiation, amplification, and resolution of chronic inflammatory processes (Rabinovich et al. 2002) .
Galectin-1 is a prototype galectin with one carbohydrate recognition domain (CRD) that can exist as a monomer or dimer with two identical CRDs that have affinity for poly-N-acetyl-lactosamine-enriched glycoconjugated proteins.
Glycosylation of proteins is the most common form of posttranslation modification and has been implicated in multiple aspects of the immune response (Bax et al. 2007 ). Galectin-1 has been shown to regulate processes such as inflammation, T-cell survival and homeostasis, platelet activation (Pacienza et al. 2008) , and host-pathogen interactions (Camby et al. 2006) , and recently it has been shown to play a role in the MHC II and Fcγ R1 expression in monocyte/macrophages (Barrionuevo et al. 2007) . Galectin-1 is expressed by numerous cell types of the cardiovascular system including endothelial cells (Thijssen et al. 2008) where it is upregulated in response to pro inflammatory stimuli (Norling et al. 2008) , smooth muscle (Moiseeva et al. 2000 (Moiseeva et al. , 2003 Chellan et al. 2007) , and cells of the monocyte/macrophage lineage (Fulcher et al. 2006; Stewart et al. 2008) .
Monocytes are produced in the bone marrow and then enter the blood where they are exposed to numerous environmental signals such as cytokines and immunoregulatory factors. When monocytes leave the circulation to enter tissues, they eventually mature into macrophages to carry out their main functions. These functions include chemotaxis toward bacteria or sites of inflammation with subsequent phagocytosis and digestion of dead or foreign material and antigen presentation (Hoffbrand et al. 2001) . The migration of peripheral circulating monocytes into tissues is considered an important process in the immune response, including inflammatory reactions. The upregulated expression of adhesion molecules on endothelial cells coupled with the chemotactic influence of novel cytokines plays a significant role in monocyte migration, localization, and activation within tissues (Barleon et al. 1996) . Monocyte migration has been implicated in pathological inflammatory reactions such as rheumatoid arthritis (Koch et al. 1992; Kunkel et al. 1996) , glomerulonephritis (Kincaid-Smith et al. 1989; Magil and Cohen 1989; Cattell 1994) , and the formation of atherosclerotic plaques (Harrington 2000; Takahashi et al. 2002) . Galectins, particularly galectin-1 and -3, have been implicated in the development of atherogenesis (Arar et al. 1998; Chellan et al. 2007; Nachtigal et al. 2008) , a process which is initiated by the transmigration of monocytes to the subendothelial space (Ashida et al. 2001) .
The involvement of galectins in chemotaxis has previously been reported for galectin-3 which stimulates both monocyte and macrophage chemotaxis (Sano et al. 2000; Papaspyridonos et al. 2008 ) and galectin-9 (Hirashima 1999; Matsumoto et al. 1998) which is a selective chemoattractant for eosinophils.
Given that both galectins and protein glycosylation are known to play a role in the regulation of the immune response and that galectin-1 is expressed by cells of the cardiovascular and immune systems, we sought to determine whether galectin-1 might be involved in monocyte chemotaxis. In addition, we carried out studies to investigate what signal transduction pathways might be involved in galectin-1-induced chemoattraction. Our study revealed that galectin-1 is chemotactic for monocytes but not macrophages and that galectin-1-induced migration of monocytes is mediated by a pertussis toxin (PTX)-sensitive pathway and by the P44/42 MAP kinase pathway.
Results

Galectin-1 induces monocyte migration in vitro
Using a 48-well microchemotaxis chamber and 5 μm polycarbonate filters, we found that human recombinant galectin-1 (1-100 μg/mL) induces monocyte migration in a dose-dependent manner (Figure 1 ) with 10 μg/mL giving a maximal response (at 10 μg/mL, P < 0.05 versus control, n = 38). Our results also show that at 10 μg/mL, galectin-1 stimulated a greater degree of monocyte migration than 100 ng/mL MCP-1 (P < 0.05), a potent chemoattractant for monocytes at this concentration (Sano et al. 2000) (Figure 2 ). To ensure that the effect on monocyte migration was due to galectin-1, experiments were carried out using anti-galectin-1 antibodies. In these experiments, monocyte migration was inhibited by 95% (P < 0.05, n = 6, Figure 2) . A control polyclonal antibody did not inhibit migration (data not shown). Furthermore, the antigalectin-1 antibody inhibited migration below control values (P < 0.05, n = 6, Figure 2 ).
The cells adhering to the polycarbonate membrane were confirmed as monocytes by immunolabeling with the monocyte marker CD68. To ensure that we were looking at migration of monocytes, we carried out some experiments on mononuclear cells that had been cultured for 30 min. The adherent monocytes were detached from the dish with EDTA and used in chemotaxis experiments. Using 10 μg/mL galectin-1 as a chemoattractant, we found no significant difference in cell migration between these cells and freshly isolated mononuclear cells. 2563 ± 432 cells migrated compared to 2738 ± 371 in the total mononuclear cell population (n = 6).
To determine whether the observed migration induced by galectin-1 was due to chemotaxis (cell migration is strictly a consequence of chemoattraction activity) or chemokinesis (cell migration due to activation of the cells that results in enhance movement in all directions), we carried out a checkerboard analysis using serial dilutions of galectin-1 above and below the filter. As shown in Figure 3 , monocyte migration depended on the presence of a galectin-1 gradient between the upper and lower face of the filter suggesting that galectin-1 induces monocyte chemotaxis rather than chemokinesis.
Galectin-1-induced chemotaxis is partially blocked by lactose
In order to determine whether the chemoattractant activity of galectin-1 is dependent on its lectin binding activity, we carried out migration assays in the presence of 30 mM lactose. We found that monocyte migration was reduced by approximately 65% (over and above the RPMI background migration) whereas the chemotactic activity of MCP-1 was not affected (Figure 2) . The negative control, sucrose which does not bind to galectin-1, did not inhibit galectin-1-induced chemotaxis but appeared to stimulate monocyte migration. Thus, these results show that the chemotactic activity of galectin-1 is at least partially dependent on CRD. 
Galectin-1 stimulates monocyte chemotaxis via the p44/42 MAPK pathway and by a PTX-sensitive pathway
Galectin-1 has been shown to activate the p44/42 MAP kinase pathway (Maeda et al. 2003; Barrionuevo et al. 2007 ); therefore, in order to determine whether the p44/42 MAP kinase pathway is involved in galectin-1, we carried out chemotaxis experiments using the MEK inhibitors PD98059 and U0126. We show that the chemotactic response of monocytes to galectin-1 is significantly blocked in the presence of both of these inhibitors (P < 0.05, n = 3, Figure 4) . Next, Western blots were undertaken to analyze p44/42 MAP kinase phosphorylation in response to galectin-1 treatment of monocytes. The results showed a galectin-1-induced increase in phosphorylation within 10 min that diminishes by 30 min ( Figure 5A ). Both the MEK inhibitors PD98059 and U0126 blocked this response ( Figure 5B ). 6 . Galectin-1 is not chemotactic for macrophages. Monocytes or macrophages were added to the upper chambers and 10 μg/mL galectin-1 was applied to the lower chambers, and the migration assay was carried out as detailed in Material and methods. Results are the means of a minimum of four experiments ± SEM.
As it is well documented that many chemoattractants use G-protein-coupled receptors to transduce signals into the cell, we investigated whether G-proteins might be involved in monocyte migration using galectin-1. Monocytes were incubated with 1 μg/mL of the G-protein inhibitor PTX in the upper chamber and 10 μg/mL galectin-1 in the lower chamber. This concentration of PTX did not affect monocyte viability (Sano et al. 2000, unpublished observations) . The results show that PTX significantly inhibited chemotaxis induced by 10 μg/mL galectin-1 (P < 0.05, n = 16) suggesting that a PTX-sensitive G-protein is involved in chemotaxis stimulated by galectin-1.
Galectin-1 does not induce migration of macrophages
Fewer chemokines have been shown to be chemoattractive for macrophages than monocytes (Zlotnik et al. 1999) . Of those that have been identified, a member of the galectin family, galectin-3, has been shown to induce both monocyte and macrophage chemotaxis (Sano et al. 2000) . To determine whether galectin-1 acts in a similar manner to galectin-3, we used human macrophages obtained by culturing peripheral blood monocytes (Sano et al. 2000) . Unlike control monocytes, cultured macrophages did not migrate in response to galectin-1 (Figure 6 ).
Discussion
The results of this study show that galectin-1 is a chemoattractant for monocytes but not macrophages. Relatively high concentrations of galectin-1 (10 μg/mL, 0.7 μM) (Camby et al. 2006 ) induce monocyte migration in vitro, and this effect can be blocked by antibodies directed against galectin-1. Interestingly, our results also suggest that endogenous galectin-1 produced by the monocytes is able to promote monocyte migration as basal levels of migration observed in our experiments are largely inhibited by anti-galectin-1 antibodies. The chemotactic response of galectin-1 is at least partially due to the carbohydrate binding function of this protein as illustrated by the attenuation of chemotaxis (65% reduction) in the presence of lactose. Galectin-1 only exhibits β-galactoside-binding activity when it is in the reduced form (Horie and Kadoya 2004) suggesting that the galectin-1 used in our experiments is predominantly in the reduced form. In the oxidized form, galectin-1 Galectin-1 stimulates monocyte chemotaxis is able to promote axonal regeneration at low concentrations (nM) by a mechanism not involving CRD. Thus, it acts as a cytokine, not as a lectin at these concentrations (Horie and Kadoya 2004) .
Other galectins have been reported to act as chemoattractants. Galectin-9, a tandem repeat galectin with 2 CRDs is chemotactic selectively for eosinophils (Hirashima 1999; Matsumoto et al. 2002) , and galectin-3 has been shown to be chemotactic for both monocytes and macrophages (Sano et al. 2000) . Like galectin-1, galectin-3-induced monocyte chemotaxis has been shown to be inhibited by lactose indicating that the carbohydrate binding domain is important in this response (Sano et al. 2000) . We also observed that the control sugar sucrose did not block galectin-1-stimulated monocyte migration but increased the migration seen. Sucrose alone also stimulated monocyte migration. Sucrose (but not lactose) at concentrations above 10 mM has been reported to promote chemotaxis in corneal endothelial cells but not in several other cell types (Vogel et al. 1993) .
It is of interest that galectin-1 was not found to be chemoattractive for macrophages. Fewer chemoattractants for these cells have been described. However, galectin-3, a single CRD galectin, has been shown to induce migration in both monocytes and macrophages but not lymphocytes or eosinophils (Sano et al. 2000) . Galectin-1 behaves more like a stereotypic chemoattractive protein MCP-1 which is only chemoattractive for monocytes. Like MCP-1, the chemoattractant activity of galectin-1 is dependent on activation of the p44/42 MAP kinase pathway (Jiménez-Sainz et al. 2003; Arefieva et al. 2005 ) and a PTXsensitive G-Protein (Baggiolini 1998) . Both the MEK inhibitors we employed reduced monocyte migration to values less than the control suggesting that basal migration also requires the p44/42 MAP kinase pathway. The activity of galectin-3 on monocytes is also inhibited by PTX although the migration of macrophages in not affected (Sano et al. 2000) . To date little is known about the receptors or signal transduction pathways involved in galectin-1. Extracellular galectins may interact with glycoproteins in the extracellular matrix to form a glycoprotein lattice or act as soluble ligands to crosslink with the carbohydrates of surface proteins by N-terminal oligomerization, thus evoking signal transduction (Rabinovich et al. 2002) . Galectin-1 binds to CD43 and CD45 on T cells: two glycoproteins that are also expressed on monocytes (Nguyen et al. 2001; Elola et al. 2005; Norling et al. 2008) . The p44/42 MAP kinase has been implicated in galectin-1-mediated proliferation of hepatic stellate cells (Maeda et al. 2003) and in FcγRI-and MHC-II-dependent functions in monocytes (Barrionuevo et al. 2007 ).
These results show that galectin-1 is chemoattractive for monocytes in vitro.
This begs the question as to whether, like galectin-3 (Sano et al. 2000) , galectin-1 is chemoattractive in vivo. Galectin-1 is expressed by smooth muscle cells of the vessel wall and is involved in adhesion, migration, and proliferation of vascular smooth muscle cells (Moiseeva et al. 2000 (Moiseeva et al. , 2003 which are key steps in the development of atherosclerosis. Galectins may, alongside MCP-1 and chemokine receptor 2, play a crucial role in the initiation of atherosclerosis by recruiting monocytes to the vessel wall. Indeed galectin-1 expression is upregulated when endothelial cells are activated (Lotan et al. 1994; Baum et al. 1995; Norling et al. 2008; Thijssen et al. 2008 ) and galectin-1 binds lipoprotein (a) (Chellan et al. 2007 ), a modified LDL molecule implicated in atherogenesis.
In conclusion, galectin-1 is a potent chemoattractant for monocytes. It joins other members of the galectin family in its ability to induce chemotaxis possibly by crosslinking of cell surface glycoproteins through their structurally conserved CRDs. These observations suggest that galectins may be involved in chemoattraction at sites of inflammation in vivo and may contribute to disease processes such as atherosclerosis.
Material and methods
Cell culture
Peripheral blood mononuclear cells were isolated from venous blood of healthy donors of both genders by gradient centrifugation on Histopaque 1077 (Sigma, UK, Stewart et al. 2008) . The cells were resuspended in RPMI-1640 medium (Invitrogen, UK) supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin (Invitrogen, UK). Cell viability, determined by trypan blue (Sigma, UK) dye exclusion, was > 95%.
In some experiments, the mononuclear cells were plated onto tissue culture plastic for 30 min allowing monocytes to adhere and lymphocytes to remain in suspension. After washing three times with PBS, cells were detached from the dish using 5 mM EDTA and used in chemotaxis assays.
For macrophage experiments, mononuclear cells were cultured for 6-8 days in RPMI-1640 containing 10% FCS and 100 IU/mL penicillin and 100 μg/mL streptomycin. Cells were allowed to attach to tissue culture plastic for 3 h after which the plates were washed five times (to remove unattached lymphocytes), and then cultured in a fresh medium (Stewart et al. 2008) . Macrophages used in chemotaxis experiments were passaged in 5 mM EDTA.
In vitro chemotaxis assay
Mononuclear cells were assayed for their ability to migrate through a porous polycarbonate membrane (5 μm pore) toward various different experimental agents using a 48-well modified Boyden chamber (Neuroprobe, USA). Cell suspensions of 2.5 × 10 4 cells per well was added to the upper compartment of the chamber and medium containing chemotactic agents in the lower part. In assays using inhibitors (50 μM PD98059 or 10 μM U0126, Roche, UK, and rabbit polyclonal anti-galectin-1 antibodies, 5 μg/mL, Peprotech, London, UK), cells were preincubated with these reagents for 30 min at 37
• C. Cells were introduced into the upper chamber in the presence of inhibitors, and galectin-1 was added to the lower chamber. The chamber was incubated at 37
• C with 5% CO 2 for 2 h, after which nonmigrated cells on the top surface of the membrane were removed using a cell scraper and the membrane washed in PBS. Remaining cells on the bottom of the membrane were fixed in 4% paraformaldehyde for 15 min and labeled as described below.
Checkerboard analysis
Checkerboard analysis to differentiate between chemotaxis and chemokinesis was performed by placing 50 μL of serial dilutions of galectin-1 (10 μg/mL, 0.7 μM) (kind gift from Professor L. Baum, prepared and assayed as detailed in Pace et al. (2003) ) in the lower wells of the modified Boyden chamber and by placing serial dilutions in the upper wells with monocytes. A migration assay was carried out as described above.
Immunohistochemistry
In order to determine that the migrated cells were monocytes, the membranes were immunolabeled with an anti-CD 68 antibody (Vector Labs, UK). Post fixing, the membranes were washed three times in PBS, incubated in 4% bovine serum albumin (BSA) for 30 min to inhibit nonspecific binding, and washed again three times in PBS. Cells on the membrane were permeabilized with 0.1% Triton ×100 for 10 min and incubated with a monoclonal mouse anti-CD 68 antibody for 1 h before being incubated in anti-mouse biotin for 1 h. Membranes and adherent cells were washed in PBS before being incubated in Streptavidin-Alexa fluor 488 (Invitrogen, UK) for 1 h and finally exposed to in DAPI (1 μg/mL) for 5 min. Membranes were mounted on microscope slides to observe and count adherent using a Leica DM5000 B microscope with ×10, ×20, and ×40 objectives. All incubations were carried out at room temperature.
Western blotting
For each condition, 6 × 10 6 peripheral blood mononuclear cells were plated on tissue culture plastic and allowed to attach for 3 h. Afterward the medium was changed to remove unattached lymphocytes. Cultures were treated with 10 μg/mL galectin-1 for a time course of 10, 15, 30, or 60 min, cells being lysed by incubation with the extraction buffer consisting of 2% sodium dodecyl sulfate (SDS), 5 mM Tris, pH 6.8, 2 mM EDTA, 2 mM EGTA, 1× protease inhibitors, and 1 mM PMSF. Samples were separated by SDS-PAGE using 12% gels for 40 min at 200 v. Proteins were transferred to a PVDF membrane (GE Healthcare, UK), blocked in 3% BSA for 30 min followed by overnight incubation in rabbit polyclonal anti-phospho p44/42 MAPK (1:1000) or anti-p44/42 MAPK (1:1000, Cell Technology, UK) antibodies. Membranes were then washed three times in PBS containing 0.1% Tween 80 and incubated in an antirabbit biotin secondary antibody (1:1000, Sigma, UK) for 1 h. After washing, membranes were incubated in streptavidin peroxidase (1:3000) for 1 h. All antibodies were diluted in PBS containing 0.1% Tween. Membranes were washed three times in PBS 0.1% Tween 80 before being developed with a 3,3 -diaminobenzidine (DAB) substrate kit (Vector Labs, UK) for peroxidase according to the manufacturer's instructions. In additional experiments, cell cultures (1 × 10 6 cells) were treated with 10 μg/mL galectin-1 and inhibitors PD98059 (50 μM) or U0126 (10 μM) for 10 min before extracts were prepared.
Statistical analysis
All experiments were carried out a minimum of three times.
All results are expressed as mean ± SEM. Significance was determined using a Student's t-test
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